biotech · Glioblastoma · Recurrent Brain Metastases · GTBP
GT Biopharma
GT Biopharma is a biotech organization headquartered in Brisbane, USA. It trades on NYSE under ticker GTBP. Primary therapeutic focus areas include Glioblastoma, Recurrent Brain Metastases, High-risk Myelodysplastic Synd
Brisbane, USA HQ
1973 Founded
8 Employees
Public company Type
GTBP · NYSE Ticker
Company details
- Status
- Public
- HQ
- Brisbane, USA
- Founded
- 1973
- Employees
- 8
- Programs
- 8
- Drugs
- 7
- Patents
- 1
GTB-3550 TriKE® Phase I
Phase 2 · small molecule · High-risk Myelodysplastic Syndromes
GTB-3550 TriKE® Phase I for High-risk Myelodysplastic Syndromes is a Phase 2 program (small_molecule) at GT Biopharma with 1 ClinicalTrials.gov record(s).
Internal code 2015LS167
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- GT Biopharma
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- High-risk Myelodysplastic Syndromes
- Status
- terminated
- Trials
- 1